Following the publication of the Drug Profile by A James Mamary and Gerard J Criner ‘Tiotropium bromide for chronic obstructive pulmonary disease’, published in the June 2009 issue of Expert Review of Respiratory Medicine (Expert Rev. Resp. Med. 3[3], 211–220 [2009]), it has been brought to our attention that the following sentence on page 211 was incorrectly printed as:
“Tiotro forced expiratory volume in 1 s pium bromide inhalational powder was approved by the US FDA in January 2004 for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.”
The correct sentence is shown below:
“Tiotropium bromide inhalational powder was approved by the US FDA in January 2004 for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.”
The editors of Expert Review of Respiratory Medicine would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.